FTC Urges 11th Circ. To Revive Pay-For-Delay Case
The Federal Trade Commission has launched the latest salvo in a battle with Watson Pharmaceuticals Inc. and others over settlements that blocked generic versions of testosterone replacement drug AngroGel, claiming that...To view the full article, register now.
Already a subscriber? Click here to view full article